AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
|Articles|August 26, 2020
Biovista Uses Artificial Intelligence to Address COVID-19
Author(s)Pharmaceutical Executive Editors
Bioscience firm applies AI and data science to identify existing drugs Atozet and Cablivi as potentially effective therapies for blood clots and inflammation caused by COVID-19.
Advertisement
Two newly repositioned drugs with the potential to combat key symptoms of COVID-19 were announced on Aug. 25 by bioscience firm
This follows a mechanistic rationale Biovista released in March, suggesting Aprotinin and Irbesartan as potential COVID-19 treatments to reduce the effects of the cytokine storm, as well as helping reduce viral loads.
For more information, click
Advertisement
Related to this article
FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists for a potential NAION risk, and AstraZeneca acquires Omniose to add a bioconjugation platform to its vaccine pipeline.
AstraZeneca acquires Omniose, to bolster it's preclinical infectious disease programs.
FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.
FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
Ignite Proteomics’ senior clinical research scientist discusses how flaws in testing tumors may lead to some patients not receiving the correct treatment.
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Requests Updated Safety Label Warning Across All GLP-1 Receptor Agonist for Potential Risk of NAION
2
AstraZeneca Acquires Omniose, Adding Bioconjugation Platform to Vaccine Pipeline
3
FDA Approves asundexian for Secondary Stroke Risk Reduction
4
Where AI Can Strengthen Clinical Research, and Where Patient Input is More Important
5